好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

REM Sleep Behavior Disorder Is Associated with Reduced Alzheimer's Pathology, Hippocampal and Parietotemporal Atrophy in Dementia with Lewy Bodies
Aging and Dementia
S44 - (-)
006
RBD is characterized by coordinated motor behavior during REM sleep with accompanying loss of muscle atonia. RBD is a suggestive feature of DLB, along with cognitive impairment, and three core features: Parkinsonism, fluctuations, and visual hallucinations. Patients with Lewy body-related neuropathology at autopsy often have concomitant Alzheimer's disease pathology, which is associated with hippocampal atrophy on MRI.
Using DLB consortium pathology criteria, we identified 75 consecutive low-to-high likelihood autopsy-confirmed DLB cases from the Mayo Clinic AD Research Center who had undergone antemortem MRI with probable-RBD (n=35) and without probable-RBD (n=40). Pathologic burden of hyperphosphorylated neurofibrillary-tau, ?-synuclein, and ?-amyloid from the hippocampus was quantified. Atlas-based quantification of hippocampal volumes and voxel-based analysis of antemortem MRIs were performed.
Hippocampal neurofibrillary-tau (p=0.007) and ?-amyloid burden (p<0.001) was lower, hippocampal and parietotemporal cortical volumes were larger in those with a history of probable-RBD compared to those without a history of probable-RBD. An ordinal logistic regression model with antemortem imaging and DLB clinical features predicting a higher likelihood of autopsy-confirmed DLB, showed a trend for hippocampal volume (odds-ratio=1.13,p=0.08) and a history of probable-RBD increased the odds (odds-ratio=5.78,p=0.004) of predicting pathology associated with DLB-likelihood. Parkinsonism approached significance (p=0.10) in a model with hippocampal volume and probable-RBD, but not fluctuations or visual hallucinations.
Presence of probable-RBD is associated with less severe Alzheimer's pathology and Alzheimer's-like atrophy in low-to-high likelihood DLB. Our data suggests that the presence of RBD is a stronger predictor of DLB likelihood than the currently established core features.
Authors/Disclosures
Melissa Murray, PhD (Mayo Clinic)
PRESENTER 		Dr. Murray has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Avid Radiopharmaceuticals. The institution of Dr. Murray has received research support from National Institute on Aging. The institution of Dr. Murray has received research support from Alzheimer's Association. The institution of Dr. Murray has received research support from Chan Zuckerberg Initiative.
Tanis J. Ferman, PhD (Mayo Clinic Jacksonville) Ms. Ferman has nothing to disclose.
Bradley F. Boeve, MD, FAAN (Mayo Clinic) Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
Scott Przybelski Scott Przybelski has nothing to disclose.
No disclosure on file
Timothy Lesnick No disclosure on file
No disclosure on file
Prashanthi Vemuri, PhD (Mayo Clinic) The institution of Dr. Vemuri has received research support from NIH.
Matthew Senjem (Mayo Clinic) Matthew Senjem has received stock or an ownership interest from Align Technology, Inc.. Matthew Senjem has received stock or an ownership interest from Inovio Biomedical Corp.. Matthew Senjem has received stock or an ownership interest from Johnson & Johnson. Matthew Senjem has received stock or an ownership interest from Mesa Laboratories, Inc.. Matthew Senjem has received stock or an ownership interest from Nvidia Inc.. Matthew Senjem has received stock or an ownership interest from LHC Group, Inc.. Matthew Senjem has received stock or an ownership interest from Natus Medical Incorporated. Matthew Senjem has received stock or an ownership interest from Varex Imaging Corporation. Matthew Senjem has received personal compensation in the range of $100,000-$499,999 for serving as a IT Technical Specialist II with Mayo Clinic.
Brittany Dugger, BS No disclosure on file
David S. Knopman, MD, FAAN (Mayo Clinic) Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
No disclosure on file
Joseph E. Parisi, MD (Mayo Clinic) Dr. Parisi has nothing to disclose.
Michael Silber, MB, ChB, FAAN (Mayo Clinic) Dr. Silber has received publishing royalties from a publication relating to health care. Dr. Silber has received personal compensation in the range of $500-$4,999 for serving as a Topic writer with UpToDate.
Christian Kamm, MD (Inselspital Bern) No disclosure on file
Neill R. Graff-Radford, MD, FAAN (Mayo Clinic Jacksonville) The institution of Dr. Graff-Radford has received research support from Biogen. The institution of Dr. Graff-Radford has received research support from Lilly. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Biogen. Dr. Graff-Radford has received publishing royalties from a publication relating to health care.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic) Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Clifford R. Jack, Jr., MD (Mayo Clinic) The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.
Dennis W. Dickson, MD (Mayo Clinic) Dr. Dickson has nothing to disclose.
Kejal Kantarci, MD (Mayo Clinic) The institution of Dr. Kantarci has received research support from Eli Lilly. The institution of Dr. Kantarci has received research support from NIH. The institution of Dr. Kantarci has received research support from ADDF.